再鼎医药(ZLAB)今日盘中大涨5%,主要受多家投行看好该股未来发展前景所推动。
中金发布研报称,维持再鼎医药"跑赢大市"评级,并将目标价上调22.5%至34.41港元。该行认为,再鼎医药去年业绩优于预期,主要受益于核心产品艾加莫德(Efgartigimod)收入高企。公司给出今年收入指引为5.6亿至5.9亿美元,第四季度实现盈利持平。中金期待再鼎医药今明两年将有大量催化剂,包括有望在今年上半年就ZL-1310和Bemarituzumab分别公布数据和递交上市申请,明年也将看到KarXT商业化进程。
花旗将再鼎医药目标价轻微上调至71美元,给予"买入"评级。该行认为,今年渠道数据、Vygart的增长,以及2026年KarXT获准上市的前景,将重新激发投资者对该股的热情。高盛也将再鼎医药目标价上调至42.01港元,重申2025年是该公司的发展里程碑年。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.